Ebna1-Specific T Cell Responses During Persistent Rhesus Lcv infection and The Development of a Novel Therapeutic Prototype Vaccine for Ebv-Associated Diseases

Thumbnail Image
Degree type
Doctor of Philosophy (PhD)
Graduate group
Cell & Molecular Biology
EBV vaccine
Allergy and Immunology
Cell Biology
Immunology and Infectious Disease
Medical Immunology
Grant number
Copyright date
Related resources

The impact of EBV on human health is substantial, but vaccines that prevent primary EBV infections or treat EBV-associated diseases are not yet available. The Epstein-Barr nuclear antigen 1 (EBNA1) is an important target for vaccination because it is the only protein expressed in all forms of latency and in all EBV-associated malignancies. The overarching goal throughout this dissertation was to determine if EBNA1 is a suitable target for vaccine development. This was addressed in two ways. First, because an improved understanding of EBNA1-specific T cell responses benefits EBV vaccine development, we characterized responses against EBNA1 of the EBV-homologous rhesus lymphocryptovirus (rhLCV) in naturally infected rhesus macaques. We assessed frequency, phenotype, and cytokine production profiles of rhesus (rh)EBNA1-specific T cells by intracellular cytokine staining (ICS) and polychromatic flow cytometry. We found that most naturally infected animals had CD4+ and/or CD8+ T cells against rhEBNA1 and rhBZLF1, an immediate-early lytic phase antigen of rhLCV. Peptide-specific CD8+ T cells showed a more activated effector phenotype, while most peptide-specific CD4+ T cells exhibited a resting central memory phenotype. T cells were highly functional and produced various combinations of the cytokines IFN-γ, IL-2, and TNF-α. The differentiation status and functional profiles of rhEBNA1-specific T cells suggests they are not impaired by chronic exposure to low levels of antigen, and rhEBNA1-specific T cells therefore represent a viable population to target through vaccination. Similarities between our findings and the human response further validate the rhLCV model for studying chronic EBV infection and for pre-clinical vaccine development. We then asked if vaccination could expand functional rhEBNA1-specific T cells during persistent rhLCV infection. To test this, we developed two serologically distinct replication-defective adenoviral vectors that expressed chimeric rhEBNA1 constructs fused to functional and non-functional versions of Herpes Simplex Virus- glycoprotein D (HSV-gD). HSV-gD has been shown to augment T cell responses by inhibiting the immunosuppressive Herpes Virus Entry Mediator (HVEM) pathway during T cell activation. After confirmation of vaccine specificity and antigenicity in vitro, rhesus macaques were vaccinated in a prime-boost regimen, and responses in peripheral blood were measured by ICS and polychromatic flow cytometry. Importantly, we found that vaccination induced the expansion of highly functional rhEBNA1-specific CD8+ and CD4+ T cells in vivo, regardless of HSV-gD binding ability. Vaccination did not increase rhBZLF1-specific T cell responses, thus indicating that rhEBNA1-specific responses were vaccine-driven. Overall, these results serve as important proof-of-principle analyses of a therapeutic EBNA1-based vaccine regimen and demonstrate that EBNA1 is a viable target that warrants exploration in future vaccine studies.

Hildegund C. Ertl
Date of degree
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Volume number
Issue number
Publisher DOI
Journal Issue
Recommended citation